Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.60 |
| ▸ | PRKCG | P05129 | 5/20 | 0.60 |
| ▸ | PRKCB | P05771 | 5/20 | 0.60 |
| ▸ | PRKCA | P17252 | 5/20 | 0.60 |
| ▸ | PRKCH | P24723 | 5/20 | 0.60 |
| ▸ | PRKCI | P41743 | 5/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.60 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | PRKACA | P17612 | 3/20 | 0.60 |
| ▸ | PRKACG | P22612 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30075444 | 1.00 | CA1 (0.61) | CA1CA2CA9CYP3A4PRKD3 | |
| Hydrochloric Acid SCHEMBL9483668 | 0.98 | LMNA (0.61) | CA1CA2CA9CYP3A4PRKD3 | |
| Hydrochloric Acid SCHEMBL29748700 | 0.98 | LMNA (0.61) | CA1CA2CA9CYP3A4PRKD3 | |
| SCHEMBL31527752 | 0.98 | CA1 (0.59) | CA1CA2CA9CYP3A4PRKD3 | |
| Ethylenediamine SCHEMBL4696234 | 0.94 | CYP3A4 (0.66) | CA1CA2CA9CYP3A4PRKD3 | |
| Quinoline SCHEMBL28307727 | 0.87 | CA1 (0.51) | CA1CA2CA9CYP3A4PRKD3 | |
| SCHEMBL18019196 | 0.86 | CA2 (0.61) | CA1CA2CA9CYP3A4PRKD3 | |
| SCHEMBL6967362 | 0.85 | CYP3A4 (0.59) | CYP3A4PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL117745 | 0.82 | CYP3A4 (0.56) | CYP3A4PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL13677595 | 0.82 | CYP3A4 (0.58) | CYP3A4PRKD3PRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| US-20240287027-A1 | PREPARATION METHOD FOR COMPOUND FASUDIL HYDROCHLORIDE | EAST CHINA UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) | 2024-08-29 | — | — | US | claimed |
| WO-2024017856-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | claimed |
| WO-2022262548-A1 | PREPARATION METHOD FOR COMPOUND FASUDIL HYDROCHLORIDE | 华东理工大学 | 2022-12-22 | — | — | WO | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| CN-113372329-B | Preparation method of fasudil hydrochloride compound | 华东理工大学 | 2022-10-18 | — | — | CN | claimed |
| EP-3702445-A2 | NOVEL MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-09-02 | — | — | EP | claimed |
| CN-111225974-A | Novel musculoskeletal system stem cells | 雪拉托兹治疗株式会社 | 2020-06-02 | — | — | CN | claimed |
| EP-3643777-A1 | NOVEL MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-04-29 | — | — | EP | claimed |
| US-10576106-B2 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2020-03-03 | — | — | US | claimed |
| EP-0669322-B1 | Substituted sulfonamides, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-09-15 | — | — | EP | claimed |
| WO-1999004775-A9 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | ONTOGENY INC (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999020298-A1 | REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | ONTOGENY, INC. (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999010004-A2 | REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | ONTOGENY, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999000117-A2 | NEUROPROTECTIVE METHODS AND REAGENTS | ONTOGENY, INC. (US) | 1999-01-07 | — | — | WO | claimed |
| EP-0526342-B1 | Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-12-04 | — | — | EP | claimed |
| EP-0691852-A1 | PRODRUGS WITH ENHANCED PENETRATION INTO CELLS | D-PHARM, LTD. (IL) | 1996-01-17 | — | — | EP | claimed |
| EP-0669322-A1 | Substituted sulfonamides, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-08-30 | — | — | EP | claimed |
| WO-1994022483-A2 | PRODRUGS WITH ENHANCED PENETRATION INTO CELLS | D-PHARM, LTD. (IL) | 1994-10-13 | — | — | WO | claimed |
| EP-0526342-A1 | Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-02-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287027-A1 | PREPARATION METHOD FOR COMPOUND FASUDIL HYDROCHLORIDE | BAD, CASP5, REN | CA1 4406/4885CA2 1843/4885CA9 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.